Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,530 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05986240 | Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML | recruiting | Phase 1 | 38 | Montefiore Medical CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT06472128 | Novel Digital Application for Patients With Acute Leukemia(NAVIGATE) | recruiting | N/A | 200 | Massachusetts General HospitalOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04260022 | Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL | recruiting | Phase 1 | 242 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Nov 5, 2025 | clinicaltrials |
| NCT05031897 | Two Step Haplo With Radiation Conditioning | recruiting | Phase 2 | 63 | Thomas Jefferson UniversityOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT05236764 | Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion(HAPLOTAB) | active not recruiting | N/A | 3 | Baylor College of MedicineOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT02756962 | Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance | active not recruiting | Phase 2 | 107 | Washington University School of MedicineOTHER | 1 | Oct 28, 2025 | clinicaltrials |
| NCT03513484 | Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia | active not recruiting | Phase 1 | 44 | Northwestern UniversityOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT04678401 | IS-free Treg HaploHCT | recruiting | Phase 1 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT02508038 | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | recruiting | Phase 1 | 22 | University of Wisconsin, MadisonOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT04986657 | Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS | recruiting | N/A | 325 | Washington University School of MedicineOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT07214064 | Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation | not yet recruiting | Phase 2 | 27 | University Hospital TuebingenOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT07014462 | A Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML(DLIT-AML) | enrolling by invitation | Phase 1 | 20 | University of VermontOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT04777916 | Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)(ALFAPPP) | recruiting | — | 5,000 | Acute Leukemia French AssociationOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT07205523 | High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)(HALO-SCT) | recruiting | — | 1,000 | Yigeng Cao,MD,PhDOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT05211570 | AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 78 | AB ScienceINDUSTRY | 4 | Oct 2, 2025 | clinicaltrials |
| NCT04229979 | Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2(REGAL) | active not recruiting | Phase 3 | 127 | Sellas Life Sciences GroupINDUSTRY | 10 | Oct 1, 2025 | clinicaltrials |
| NCT07201727 | CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Oct 1, 2025 | clinicaltrials |
| NCT06307054 | CLL-1 CAR-NK Cells for Relapsed/Refractory AML | recruiting | Phase 1 | 24 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07198867 | A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 20 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT06501196 | A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome | recruiting | Phase 1 | 170 | BlossomHill TherapeuticsINDUSTRY | 1 | Sep 24, 2025 | clinicaltrials |
| NCT07187505 | Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia | active not recruiting | N/A | 28 | Anhui Medical UniversityOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT02917720 | 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients(NAUT) | active not recruiting | Phase 2 | 75 | European LeukemiaNetNETWORK | 2 | Sep 22, 2025 | clinicaltrials |
| NCT04258943 | Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 60 | Children's Oncology GroupNETWORK | 8 | Sep 18, 2025 | clinicaltrials |
| NCT05823571 | Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | active not recruiting | Phase 1 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06281847 | An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia(RESOLVE AML001) | not yet recruiting | Phase 1 / Phase 2 | 143 | Advesya SASINDUSTRY | 4 | Sep 18, 2025 | clinicaltrials |
| NCT01311258 | Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome(MRD) | recruiting | — | 400 | University of RochesterOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT05871008 | Integrated Actionable Aging Assessment for Cancer Patients Pilot | active not recruiting | N/A | 35 | University of Colorado, DenverOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT05305859 | Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML | recruiting | Phase 2 | 30 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT07157514 | Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML | not yet recruiting | Phase 2 / Phase 3 | 306 | Actinium PharmaceuticalsINDUSTRY | 0 | Sep 10, 2025 | clinicaltrials |
| NCT07165535 | Quality of Life and Care Organization of Patients With Chronic Myeloid Leukemia in the Lombardy Hematology Network | recruiting | — | 2,000 | University of Milano BicoccaOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07162116 | A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants(XY0206-CQT) | recruiting | Phase 1 | 45 | Shijiazhuang Yiling Pharmaceutical Co. LtdINDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04385290 | Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)(MOSAIC) | recruiting | Phase 1 / Phase 2 | 214 | Technische Universität DresdenOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT04671693 | A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.(PASCA) | active not recruiting | N/A | 500 | Centre Leon BerardOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07022743 | Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy | active not recruiting | Phase 2 | 75 | Obafemi Awolowo UniversityOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07158294 | Identification of BCR::ABL1 Mutations by Digital PCR in CML(DiP-in-CML) | not yet recruiting | N/A | 150 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | Sep 5, 2025 | clinicaltrials |
| NCT07109518 | uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies | recruiting | Phase 1 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT07150676 | Harmonized Clinical and Biological Database for Integrated Research Into the Management of Pediatric Acute Myeloid Leukemia(DOREMy) | not yet recruiting | — | 2,000 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Sep 2, 2025 | clinicaltrials |
| NCT07146542 | Expression Pattern and Possible Clinical Significance of CD81 In Myeloid Leukemia | not yet recruiting | — | 66 | Assiut UniversityOTHER | 0 | Aug 28, 2025 | clinicaltrials |
| NCT07143877 | Prognostic Impacts of Lipid Profile and BMI in Adult AML(AML/BMI) | not yet recruiting | — | 200 | Assiut UniversityOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT07144020 | Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia | recruiting | Early Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT03850574 | Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia(TUSCANY) | recruiting | Phase 1 / Phase 2 | 240 | Aptose Biosciences Inc.INDUSTRY | 6 | Aug 26, 2025 | clinicaltrials |
| NCT07016165 | Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies | recruiting | Phase 4 | 120 | Gadjah Mada UniversityOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT07131085 | QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS) | not yet recruiting | Phase 1 | 9 | Anhui Provincial HospitalOTHER_GOV | 0 | Aug 20, 2025 | clinicaltrials |
| NCT04541056 | Goal Management Training for Adult Survivors of Childhood Leukemia and Non-Hodgkins Lymphoma With Neurocognitive Sequelae | active not recruiting | N/A | 60 | Norwegian University of Science and TechnologyOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT06378437 | A Study of GLB-001 in Patients With Myeloid Malignancies | recruiting | Phase 1 | 108 | Hangzhou GluBio Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT07075016 | Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy(EVOLVE 1) | recruiting | Phase 3 | 227 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 16 | Aug 19, 2025 | clinicaltrials |
| NCT07126782 | The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT | recruiting | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT04086264 | IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 218 | AbbVieINDUSTRY | 6 | Aug 14, 2025 | clinicaltrials |
| NCT06387069 | A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia | recruiting | Phase 3 | 316 | HutchmedINDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Nov 10, 2025source: clinicaltrials